07:00 , Aug 13, 2015 |  BC Innovations  |  Translation in Brief

Hijacking estrogen receptors

Although they've long been viewed as passive indicators of breast tumors' sensitivity to estrogen receptor blockers, a new study suggests that progesterone receptors may have an active role to play in combating breast cancer by...
07:00 , Sep 16, 2013 |  BC Week In Review  |  Company News

Cambridge Research Biochemicals, Medical Research Council deal

Supply/service company Cambridge Research Biochemicals acquired an exclusive, worldwide license to a method for parallel assembly of large numbers of peptide-cargo conjugates from the U.K. government-funded Medical Research Council. Cambridge plans to launch a service...
07:00 , Jun 28, 2012 |  BC Innovations  |  Distillery Techniques

Technology: Drug platforms

This week in techniques Approach Summary Licensing status Publication and contact information Drug platforms Cell-free circulating tumor DNA as a cancer diagnostic A method to isolate, amplify and sequence tumor-derived circulating DNA fragments could help...
07:00 , Jun 28, 2012 |  BC Innovations  |  Targets & Mechanisms

Liquid biopsy

A Cancer Research UK team has developed a diagnostic platform that uses tumor-derived circulating DNA to noninvasively monitor a patient's response to therapy. 1 The researchers are now moving the technology into a hospital setting,...
07:00 , May 31, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Head and neck cancer FERM domain containing 4A (FRMD4A) Patient sample and mouse studies suggest inhibiting FRMD4A could be used to treat head and neck...
08:00 , Mar 8, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Pancreatic cancer g-Secretase Studies in mice suggest inhibiting g-secretase could help treat pancreatic cancer. In a mouse model of pancreatic cancer, the g-secretase inhibitor MRK003...
08:00 , Mar 8, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Autoimmune Disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Autoimmune disease Autoimmune disease Indoleamine 2, 3-dioxygenase (INDO; IDO) Mouse studies suggest IDO could help treat and prevent autoimmune diseases. In lupus-prone mice, an IDO inhibitor...
08:00 , Nov 17, 2011 |  BC Innovations  |  Strategy

Cancer matchmaker

As pharmas increasingly look to offload early stage R&D expenses, Cancer Research Technology Ltd. , the commercial arm of biomedical charity Cancer Research UK , has seen more uptake of its partnered consortium model for...
07:00 , Jun 2, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/ pathway Summary Licensing status Publication and contact information Cancer Prostate cancer Calcium calmodulin-dependent protein kinase kinase 2b (CAMKK2); androgen receptor In vitro and mouse studies suggest CAMKK2 inhibitors could help treat prostate cancer....
08:00 , Jan 10, 2011 |  BioCentury  |  Analyst Picks & Changes

Analyst Picks & Changes

Analyst Picks & Changes Company Bank Analyst Coverage Opinion Wk chg 1/7cls Acorda Therapeutics Inc. (NASDAQ:ACOR) Leerink Joshua Schimmer Upgrade Market outperform (from market perform) 2% $27.67 Schimmer upgraded based on his monthly patient modeling...